Endogenous ligands of G protein-coupled receptors bind to orthosteric sites that are topologically distinct from allosteric sites. Certain aminothiophenes such as (2-amino-4,5-dimethyl-3-thienyl)-[3-(trifluromethyl)-phenyl]-methanone (PD81,723) and 2-amino-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-biphenyl-4-yl-methanone (ATL525) are positive allosteric regulators, or enhancers, of the human A 1 adenosine receptor (A 1 AR). In equilibrium binding assays, 125
not follow theoretical single-site association kinetics but is approximated by a bi-exponential equation with t 1/2 values of 1.85 and 12.8 min. Allosteric enhancers selectively increase the number of slow binding sites, possibly by stabilizing newly formed receptor-G protein complexes. A new rapid assay method scores enhancer activity on a scale from 0 to 100 based on their ability to prevent the rapid dissociation of 125 I-ABA from A 1 AR in response to GTP␥S. Compared with PD81,723, ATL525 (100 M) scores higher (27 versus 79) and has less antagonist activity. ATL525 functionally enhances A 1 signaling to inhibit cAMP accumulation in CHO-hA1 cells. These data suggest that simultaneously binding orthosteric and allosteric enhancer ligands convert the A 1 AR from partly to fully coupled to G proteins and prevents rapid uncoupling upon binding of GTP␥S.
Ligands that target G protein-coupled receptors generally bind to the same site as the endogenous ligand, defined as the orthosteric site. Receptors can also be influenced by compounds that bind to topologically distinct allosteric sites, as reviewed recently (Christopoulos, 2002; Christopoulos and Kenakin, 2002) . Various orthosteric ligands do not necessarily have exactly overlapping binding domains but overlap in their binding sites enough that two orthosteric ligands cannot bind at the same time. As a functional consequence, orthosteric ligands are competitive in equilibrium binding assays, and the binding of one orthosteric ligand does not affect the dissociation kinetics of another. Allosteric ligands have little or no overlap with the orthosteric site. Hence allosteric and orthosteric ligands can both bind simultaneously. As a functional consequence of binding, positive allosteric regulators decrease the dissociation kinetics of orthosteric ligands, and negative allosteric regulators increase the dissociation kinetics of orthosteric ligands. PD81,723 ( Fig. 1) is a 2-aminothiophene extensively characterized as an allosteric activator or enhancer of A 1 ARs (Bruns and Fergus, 1989; Amoah-Apraku et al., 1993; Musser et al., 1993 Musser et al., , 1999 Bhattacharya and Linden, 1995; Kollias-Baker et al., 1997; Van der Klein et al., 1999; Kourounakis et al., 2001) . Several groups have recently prepared new 2-aminothiophenes that are more potent and effective than PD81,723 as A 1 AR allosteric enhancers (Baraldi et al., 2000; Tranberg et al., 2002; Lutjens et al., 2003) . These compounds act to selectively increase the binding affinity of agonists to the A 1 AR and have little or no activity at other G protein-coupled receptors or on the other adenosine receptor subtypes A 2A , A 2B , or A 3 (Mizumura et al., 1996) . At high concentrations, some 2-aminothiophenes, including PD81,723, also act as competitive antagonists of the orthosteric site.
PD81,723 increases equilibrium agonist radioligand binding to the A 1 AR, slows agonist dissociation kinetics, and increases the functional sensitivity of tissues to A 1 AR-mediated responses in the heart and central nervous system (Janusz et al., 1991; Amoah-Apraku et al., 1993) . We have shown that it is possible to improve on the moderate enhancing efficacy of PD81,723 by modifying its structure such that the C-4 and C-5 atoms of the thiophene ring are incorporated into a cycloalkyl bridge or by adding bulky 3-aroyl-substituents (Tranberg et al., 2002) . ATL525 (Fig. 1) incorporates both of these features by including the C-4 and C-5 methyl groups in a cyclohexyl ring and by containing a 3-(p-phenylbenzoyl) substituent. In this study, we used PD81,723 and ATL525 as tools to investigate the molecular mechanisms by which A 1 allosteric enhancers influence the interactions between A 1 ARs, G proteins, and guanine nucleotides. ATL525 is more potent than PD81,723 in radioligand binding and functional assays. Both promote a slow (t 1/2 Ͼ10 min) conversion of the A 1 AR from a mixture of receptors in the lowand high-affinity states to one consisting only of high-affinity receptors coupled to G proteins. The enhancers also reduce sensitivity of agonist radioligand binding to inhibition by GTP␥S. We conclude that allosteric enhancers increase agonist binding by stabilizing the receptor-G protein complex.
Materials and Methods
Materials. PD81723 and ATL525 were synthesized as described previously (Tranberg et al., 2002 Equilibrium Binding Assays. 125 I-ABA was prepared by the chloramine-T catalyzed radioiodination of ABA with carrier-free Na 125 I followed by purification over a 25-cm C18 column using a System Gold high-performance liquid chromatograph (Beckman Coulter, Fullerton, CA) with UV detection at 268 nM and a Beckman in-line ␥-counter to detect 125 I. Chromatography was initiated with methanol/5 mM NaH 2 PO 4 , pH 6.0 (1:1) for 5 min, followed by a linear gradient of methanol to 100% over 15 min. The elution times for iodine, ABA, and 125 I-ABA are 1.5, 8, and 13 min, respectively. Membranes were prepared in buffer with protease inhibitors as described previously (Robeva et al., 1996) from CHO-K1 cells stably transfected with human A 1 adenosine receptors (CHO-hA 1 ). Membranes derived from these cells express approximately 2 pmol/mg of protein of A 1 receptors. For equilibrium binding assays membranes were prepared in buffer (10 mM HEPES, pH 7.4) and preincubated with 2 U/ml adenosine deaminase for 10 min. Aliquots of membranes (15 g of protein in 50 l) were added to the wells of 96-well Millipore (Bedford, MA) multiscreen filtration plates (GF/B filter) with 50 l/well of 125 I-ABA or [ 3 H]CPX with or without allosteric enhancers in HEPES buffer, usually with 1 mM MgCl 2 (final concentration, 0.5 mM MgCl 2 in 0.1 ml) at 21°C for 3 h. For competition binding experiments, inhibitors were added with radioligand. All of the wells were washed simultaneously using a Brandel Microdispenser with 5 ϫ 200 l of ice-cold 10 mM Tris-HCl, 10 mM MgCl 2 , pH 7.4. To determine nonspecific binding, 100 M 8-CPT was added to the membranes before the radioligand, and allosteric enhancers were omitted. We found the addition of PD81,723 or ATL525 produced an apparent increase in nonspecific binding only in membranes expressing A 1 receptors. This probably results from the very high affinity and slow dissociation of the radioligand 125 I-ABA in the presence of allosteric enhancers. For this reason, true nonspecific binding was measured in the absence of allosteric enhancers and represented Ͻ20% of total binding in all experiments. For binding isotherms, nonspecific binding was fit by least-squares regression to a straight line. Nonspecific binding calculated for each concentration of radioligand was subtracted from total binding to determine specific binding. Specific equilibrium binding was fit to a 1-or 2-site hyperbolic equation using Prism (version 3.0; GraphPad Software, San Diego, CA) For curvilinear Scatchard analyses (2-site plots of Bound versus B/F) B/F was calculated using the quadratic equation:
Optimal parameter values were determined by nonlinear least-squares interpolation (Marquardt, 1963) . All results shown in the figures are typical of 3 to 5 experiments. Each point represents the mean Ϯ S.E.M. of 3 determinations, unless otherwise indicated.
Effects of Allosteric Enhancers on GTP␥S Inhibition of 125 I-ABA Binding. Membranes from CHO-hA 1 cells were diluted to 0.3 mg protein/ml in HEPES/EDTA buffer (10 mM HEPES and 1 mM EDTA, pH 7.4) and preincubated with 2 U/ml adenosine deaminase for 15 min at 21°C.
125 I-ABA in HEPES/EDTA buffer containing MgCl 2 was added for 90 min, followed by ATL525 (25 M) or vehicle (0.4% DMSO) for 5 min. Finally, various concentrations of GTP␥S were added for 90 min. The final composition of the assay mixture was: 15 g of membrane protein, 25 M enhancer, 1 U/ml adenosine deaminase, 1.25 mM MgCl 2 , and 0.5 nM radioligand.
Association Kinetics. The rate of 125 I-ABA binding to CHO-hA 1 membranes at 30°C was measured by adding, at 90-s intervals over a 30-min period, radioligand with MgCl 2 (final concentration, 0.5 mM) Ϯ 25 M allosteric enhancer to sets of wells containing membranes pretreated with adenosine deaminase (2 U/ml for 15 min in MgCl 2 -free HEPES buffer) in a final volume of 200 l. Incubations continued until the last set of wells had incubated for 90 s, then the entire ensemble of membranes was filtered and washed simultaneously. Equilibrium (2.5 h) specific binding (B eq ) also was determined in parallel. Binding theory predicts that association to a single binding site is described by the relationship ln[B eq /(B eq Ϫ B)] ϭ K obs ϫ t where
, where K Ϫ1 is the dissociation rate constant and K 1 is the association rate constant. Theoretically, a plot of ln[B eq /(B eq Ϫ B)] versus time yields a straight line with a slope ϭ K obs . Because such a plot did not result in a straight line, association data were also fit by nonlinear leastsquares to the bi-exponential equation B ϭ B1(1 Ϫ exp(Ϫk 1 t) ϩ 
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B2(1 Ϫ exp(Ϫk 2 t); where B1 and B2 approximate the number of rapid and slow binding sites, respectively. Dissociation Kinetics. CHO-hA 1 membranes (15 g of protein in 100 l) at 21°C were preincubated with adenosine deaminase (2 U/ml) in MgCl 2 -free buffer.
125 I-ABA (final concentration, 0.7 nM with 0.5 mM MgCl 2 ) was added, and incubation continued for 90 min to achieve binding equilibrium. Either vehicle or allosteric enhancer (1-100 M in 50 l) was added, followed 5 min later by 50 l of GTP␥S and 8-cyclopentyltheophylline (final concentrations, 50 and 100 M, respectively). Data were fit to bi-exponential decay curves. Some experiments measured the dissociation kinetics of the antagonist [
3 H]CPX (2-4 nM) using a similar protocol, except that MgCl 2 and GTP␥S were omitted and data were fit to a monoexponential equation. The inhibition of 125 I-ABA dissociation by allosteric enhancers was scored between 0 and 100%, as illustrated in Fig. 5 .
Guanine Nucleotide Exchange Assays. CHO-hA 1 membranes (15 g of membrane protein in 50 l) in MgCl 2 -free buffer (10 mM HEPES, pH 7.4) were preincubated with adenosine deaminase (2 U/ml) for 10 min at 21°C. Either 50 l of vehicle (0.5% DMSO) or allosteric enhancer (25 M final) was added, followed by various concentrations of CPA in (final concetration) 10 mM HEPES, pH 7.4, 10 M GDP, 5 mM MgCl 2 , 5 g/ml saponin, 100 mM NaCl, 1 M 8-CPT, and 2 mM dithiothreitol. CPT counteracted the effects of low levels of endogenous adenosine that escaped deamination. Tubes were incubated for 30 min at 30°C. [
35 S]GTP␥S (final concentration, 0.5 nM in 10 l) was added 10 min before filtration.
Cyclic AMP Assays. CHO-hA 1 cells cultured in Ham's F12 medium with 10% fetal calf serum, 1% penicillin/streptomycin, and 250 g/ml G418 were removed from plates by incubation for 5 to 10 min with EDTA in phosphate-buffered saline. Cells were washed twice and resuspended in phosphate-buffered saline containing 10 mM HEPES and 2 U/ml adenosine deaminase, pH 7.2. Aliquots of cells (200 l, 0.75-1 ϫ 10 5 cells/tube) were transferred to polypropylene test tubes and preincubated for 30 min at 21°C. Stock concentrations of compounds in 50 l of phosphate-buffered saline/HEPES buffer containing (final concentration) 5 M forskolin and 10 M rolipram with or without allosteric enhancers or CPA were added to cells and the tubes were transferred to a 37°C shaking water bath for 10 min.
The addition of 0.5 ml of 0.15 N HCl lysed the cells. A 0.5-ml aliquot of the supernatant after centrifugation at 1700g for 10 min was removed for acetylation and radioimmunoassay of cyclic AMP (Brooker et al., 1979) .
Results
Equilibrium Binding Studies. We investigated the effects of two allosteric enhancer compounds, PD81,723, which has been extensively characterized as a moderately effective allosteric enhancer of A 1 AR in prior studies, and ATL525, recently described as a new high efficacy enhancer (Tranberg et al., 2002) . In the absence of allosteric enhancers, 125 I-ABA binds to two affinity states. The high-affinity K D is 0.33 nM. The low-affinity K D cannot be measured accurately because of high nonspecific binding at radioligand concentrations above 5 nM, but it is estimated to be ϳ10 nM (Fig. 2) . In the presence of either allosteric enhancer, binding was to a single high-affinity site. This is readily apparent in Fig. 2 as a shift in Scatchard plots from curvilinear in the absence of enhancers to linear in the presence of enhancers. The addition of either enhancer produced a Ͼ2-fold increase in the number of high-affinity binding sites. Because our previous studies have established that the high-and low-affinity sites correspond to G protein-coupled and -uncoupled receptors, respectively (Figler et al., 1996 (Figler et al., , 1997 , such a result suggests that the allosteric enhancers increase equilibrium binding primarily by stabilizing receptor-G protein complexes, resulting in a population of receptors fully coupled to G protein.
Interaction between Allosteric Enhancers and Guanine Nucleotides. The binding of guanine nucleotides such as GTP␥S rapidly uncouples receptor-G protein complexes, reducing high-affinity agonist binding. Fig. 3A shows that the addition of ATL525 opposes that effect of GTP␥S. It is noteworthy that this result does not represent an effect on binding equilibrium, because the uncoupling effect of GTP␥S is both concentration-and time-dependent. The data indicate, however, that enhancers substantially slow the reduction of high-affinity binding by GTP␥S. Two mechanisms could account for such a result. First, bound allosteric enhancer might prevent GTP␥S from binding to the G protein, either by steric hindrance, which denies access to the GTPbinding site, or by allosterically lowering affinity for the site. Alternatively, GTP␥S may bind normally, and the enhancer might retard the rapid dissociation of receptor-G complexes initiated by guanine nucleotide binding. The results shown in Fig. 3B support the latter explanation: ATL525 increases the guanine nucleotide exchange stimulated by the agonist CPA. These experiments suggest that allosteric enhancers offset the reduction in high-affinity agonist binding caused by guanine nucleotide binding.
Effects of Allosteric Enhancers on the Kinetics of 125 I-ABA Binding. We next examined the effects of the enhancers on the kinetics of 125 I-ABA binding to the A 1 AR. In Fig. 4A , binding has been transformed to plot ln[B eq /(B eq Ϫ B)] versus time. If there is a single binding site, binding theory predicts that this transformation results in a straight line with a slope of K obs . The transformed data were not linear beyond 8 min, suggesting the existence of more than one kinetically distinct binding site. A bi-exponential equation incorporating two rate constants was found to fit the association kinetics well (Fig. 4B) . The t 1/2 values for the fast and slow components of binding are 1.85 and 12.8 min, respectively, a difference of 6.9-fold. The effects of the allosteric enhancers PD81,723 and ATL425 on bi-exponential binding parameters are summarized in Table 1 . The enhancers have no effect on the number of fast binding sites, B max1 . The most striking effect of the enhancers is the increase, by Ͼ60%, in the number of slowly occupied binding sites, B max2 . Thus, there is little effect of the enhancer on rapid radioligand binding during the first 10 min. Beyond 10 min, binding in the presence of the enhancers increases above control binding. One interpretation of this result is that the rapid binding phase reflects 125 I-ABA binding to preformed receptor-G protein (R-G) complexes, whereas the slow phase represents the binding to new R-G complexes recruited from the pool of previously uncoupled receptors. This is consistent with the observation that the enhancers act to stabilize R-G complexes.
Assessment of Allosteric Enhancer Score. PD81,725 was found to have two opposing effects on equilibrium binding: it has a positive allosteric effect to increase orthosteric agonist binding, but it also has activity as a competitive antagonist and can thereby decrease equilibrium radioligand binding. An allosteric action to increase the binding of any adenosine contaminating membrane preparations may also contribute to a decrease in equilibrium radioligand binding. For this reason, determining the kinetics of agonist radioligand dissociation from the orthosteric site has been used as an unambiguous measure of allosteric activity . High-affinity agonists such as 125 I-ABA dissociate slowly (t 1/2 ϭ 34 min) from R-G complexes in the absence of guanine nucleotides (Fig. 5A ). In the presence of the allosteric enhancer PD81,724 (25 M), the t 1/2 for 125 I-ABA dissociation increases by 8.1-fold to 276 min. To measure kinetics accurately, it is necessary to conduct binding assays lasting several hours. To simplify measuring enhancer activity, we examined the effect of allosteric enhancers on the kinetics of agonist dissociation promoted by 50 M GTP␥S. In the absence of an allosteric enhancer, the addition of the guanine nucleotide caused very rapid dissociation of bound 125 I-ABA, the t 1/2 being less than 1 min (Fig. 5B ). The addition of the high efficacy enhancer ATL525 (25 M) resulted in the complete disappearance of the rapid phase of dissociation.
125 I-ABA dissociated mono-exponentially with a t 1/2 of 28 min. This GTP␥S-resistant state might reflect receptors occupied by both the orthosteric and allosteric ligands. By contrast, in the presence of PD81,725 (25 M), GTP␥S evoked a rapid and a slow phase of 125 I-ABA dissociation that could correspond to population of receptors without and with PD81,723 bound to the allosteric site, respectively. As a means of quantifying the ability of the allosteric regulators to prevent rapid dissociation of the orthosteric radioligand, we scored the enhancers on a scale of 0 to 100, as illustrated in Fig. 5B . In this system, a compound that has no effect on GTP␥S action (measured at 10 min after initiating dissociation) has a score of 0, whereas a compound completely preventing dissociation at 10 min would have the at ASPET Journals on June 3, 2017 molpharm.aspetjournals.org maximal score of 100. To conduct this assay, the orthosteric radioligand is bound to equilibrium (2 h) and then the allosteric enhancer is added 5 min before initiating dissociation with a combination of an antagonist, CPT, and GTP␥S. Five minutes is enough time for the allosteric enhancer effect to be fully evident but short enough to cause little or no change in the equilibrium binding of the radioligand.
Allosteric enhancer score was dose-dependent ( Fig. 5C ). At the highest dose used, 100 M, ATL525 and PD81,723 had scores of 79 and 28, respectively. The curve relating the concentration of ATL525 to its score as an allosteric enhancer had a Hill coefficient approaching unity (0.87). This is consistent with the possibility the enhancer score is proportional to occupancy of a single saturable allosteric site.
Effect of Allosteric Enhancers on Antagonist Binding. PD81,723 and other allosteric enhancers inhibit binding of antagonist radioligands such as [ 3 H]CPX (Bruns and Fergus, 1989 ). An example of this action of PD81,723 is illustrated in Fig. 6A . ATL525 is not only more efficacious than PD81,723 as an enhancer of agonist binding but also inhibits antagonist binding only slightly. The effect of PD81,723 to reduce equilibrium [ 3 H]CPX binding could be attributed to either a competitive or an allosteric inhibitory action. Fig. 6B shows that neither allosteric compound has any effect on the kinetics of antagonist dissociation from A 1 ARs. These data suggest that the binding of enhancers has little or no allosteric effect on antagonist binding and confirm previous reports that there is no correlation between the enhancer and antagonist activities of 2-aminothiophenes.
Functional Effects of ATL525. Although ATL525 is more potent and effective than PD81,723 as an allosteric enhancer of 125 I-ABA binding, it has not yet been shown to have functional enhancer activity. In CHO-hA1 cells, ATL525 produced a dose-dependent inhibition in cyclic AMP levels, even in the absence of CPA (Fig. 7A) . Others have noted such partial agonist activity by enhancers . In the presence of 300 nM CPX, added to reverse the partial agonist effect of ATL525, the effect of the ATL525 was manifested as a leftward shift in the dose-response curve to CPA. As shown in Fig. 7B, 3 M ATL525 enhanced the potency of CPA by 10-fold.
Discussion
Allosteric modulators of G protein-coupled receptors have been thought of as compounds that bind to receptors and either increase or decrease the binding of orthosteric ligands. The binding sites of allosteric enhancers of the A 1 AR are not known, but PD81,723 and ATL525 are both positive allosteric regulators because they decrease the dissociation kinetics of the orthosteric agonist ligand 125 I-ABA. The mathematical modeling of allosterism has been characterized by a cooperativity factor, ␣, that characterizes the strength of the interaction between the allosteric and orthosteric sites (Christopoulos, 2002) . In the present study, we have examined two positive allosteric regulators of A 1 ARs, a well characterized, moderately effective enhancer, PD81,723, and a recently synthesized, more efficacious enhancer, ATL525. This study focused on how these compounds influence the coupling of A 1 ARs to G proteins. The results indicate that both compounds act more to increase the fractional coupling of A 1 ARs to G proteins than to increase the affinity of the receptors for TABLE 1  Parameters for 125 I-ABA binding to CHO-hA 1 membranes with or without 25 M concentrations of allosteric enhancers, PD81723, or ATL525. Association kinetics from experiments conducted on the same day using the same pool of membranes and radioligand were optimally fit to a biexponential equation as described under Materials and Methods. The parameter values and S.E. are derived from least squares nonlinear regression fits. agonists. Thus, in equilibrium binding assays employing agonist radioligands, both PD81,723 (Kollias-Baker et al., 1994; Bhattacharya and Linden, 1995) and ATL525 increase the fraction of receptors found in the high-affinity (G proteincoupled) state, but have little or no effect on the radioligand K D . These findings suggest the enhancers stabilize the conformational state of receptors that bind agonists with high affinity. It is notable that enhancers fail to increase agonist binding to A 1 ARs on adipocyte membranes very highly coupled to G proteins even in the absence of enhancers (Jarvis et al., 1999) . In view of these findings, we conclude that a cooperativity factor, ␣, is not adequate to model allosteric regulation of G protein-coupled receptors and that an effect on G protein coupling also should be included. The action of enhancers to increase R-G coupling is opposite that of guanine nucleotides such as GTP␥ S, which uncouple ligand-receptor-G protein (LRG) complexes. Previous work showed that PD81,723 produced a small (2.2-fold) rightward shift in the potency of GTP␥S to decrease agonist binding (Bhattacharya and Linden, 1995) . In that study, PD81,723 and GTP␥S were added to membranes at the same time. To the extent that GTP␥S binds to G proteins before the enhancer binds to receptors, the guanine nucleotide may act to uncouple R-G complexes before the enhancer can bind. In the current study, we show that if ATL525 and 125 I-ABA are added to membranes before GTP␥S, there is a very large decrease (Ͼ100-fold) in the potency of the guanine nucleotide to decrease agonist binding measured at 90 min (Fig. 3A) . Fig. 3B shows that ATL525 enhances rather than inhibits the ability of CPA to stimulate guanine nucleotide exchange on the G protein. Together, the results suggest that the at ASPET Journals on June 3, 2017 molpharm.aspetjournals.org simultaneous binding of an enhancer and an orthosteric agonist to the R-G complex does not prevent GTP␥S from binding, but does slow uncoupling of the R-G complex.
The actions of enhancers, orthosteric agonist ligands, and GTP on the stability of the LRG complex can be conceptualized in an expansion of the classic ternary complex model of receptor-G protein interactions (De Lean et al., 1980) . Binding of the orthosteric agonist facilitates receptor-G protein coupling and the formation of the high-affinity conformational state, R*. We propose, as an expansion of the ternary complex model, that the simultaneous binding of both an allosteric enhancer, E, and ligand causes enhanced stability of R*G complex and resistance to uncoupling upon the binding of GTP. In the context of this model, the effects of enhancers on the kinetics of 125 I-ABA binding are interesting. Careful analysis of binding kinetics reveals two phases of orthosteric agonist binding. This is consistent with the possibility that a fraction of A 1 ARs in CHO-hA1 membranes are precoupled to G proteins and consequently bind agonists more quickly than receptors initially uncoupled from G proteins. Other evidence that some GPCRs are precoupled is based on: coimmunoprecipitation of R-G complexes, the kinetics of G protein activation, and the kinetics of GPCRregulated K ϩ channel activation (Shea and Linderman, 1997; Roka et al., 1999; Martin, 2002; Zhang et al., 2002) . Our experiments show allosteric enhancers selectively increase the population of receptors that bind agonists slowly (Fig. 4,  Table 1 ), consistent with the concept that this slow phase of binding reflects the gradual formation of R-G complexes and that the R-G complexes that do form are stabilized by enhancers.
The effects of allosteric enhancers on equilibrium binding of orthosteric agonists are variable because these effects depend on the coupling state of receptors and are influenced by the competitive antagonist properties of some of these compounds. Hence, the use of agonist dissociation kinetics has been used as a pure measure of allosteric enhancer activity (Bruns and Fergus, 1989) . One limitation of this assay stems from the fact that in the presence of enhancers, agonist dissociation can be very slow (see Fig. 5A ). In this study, we have developed a new procedure for rapidly assessing enhancer activity that measures resistance to the effect of GTP␥S to uncouple R-G complexes as a robust means of quantifying enhancement. The assay procedure, illustrated in Fig. 5 , exploits the fact that the GTP␥S minimally uncouples ELRG complexes over a period of 10 min. We normalize GTP␥S-resistant high-affinity agonist binding by relating it to that observed in the absence of any enhancer (0%) and no dissociation over 10 min (100%), thereby deriving an enhancer score. Note in Fig. 5B that 125 I-ABA dissociation in the presence of PD81,723 occurs in two clearly discernible kinetic phases that probably correspond to LRG complexes without (fast dissociation) and with (slow dissociation) bound enhancer. In the presence of 100 M ATL525, the LRG complexes are nearly saturated with enhancer, only slow dissociation is observed, and the score is nearly 100%. Lower doses of ATL525 generating lower scores result in biphasic dissociation kinetics (data not shown), which is consistent with the hypothesis that enhancer score is related to LRG occupancy by enhancer. In principle, it is likely that different enhancers might stabilize the ELRG complex to different extents. This would manifest itself as different rates in the slow phase of agonist dissociation.
Assessing functional responses in intact cells is an important way to evaluate the effect of enhancers to increase the potency of orthosteric agonists. In assays based on A 1 -agonist induced lowering of cyclic AMP, 30 M PD31723 was found to produce a 3-to 4-fold increase in agonist potency Linden, 1995, 1996) . By contrast, as shown in Fig. 7 , 3 M ATL525 produced a 10-fold shift in agonist potency, consistent with its greater enhancer score than PD81,723.
In conclusion, the results of this study indicate the primary effect of two allosteric enhancers of A 1 ARs is to stabilize the high-affinity agonist binding conformational state of receptor-G protein complexes. This is manifested in equilibrium binding as an increase in steady-state coupling and in kinetic assays as an increase in the fraction of slow binding as receptors convert from uncoupled to coupled over time. The potency and efficacy of enhancers can be accurately and quickly scored based on their ability to acutely counteract the action of GTP␥S to uncoupled receptor-G protein complexes. 
